Cimetropium bromide - CAS 51598-60-8

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
APIs
Product Name
Cimetropium bromide
Catalog Number
51598-60-8
CAS Number
51598-60-8
Molecular Weight
438.36
Molecular Formula
C21H28BrNO4
COA
Inquire
MSDS
Inquire
Structure
CAS 51598-60-8 Cimetropium bromide
Reference Reading
1.Infantile Colic-Unfolded
Pankaj Garg. Indian Journal of Pediatrics, Volume 71---October, 2004
Infantile colic has a multifactorial genesis with most cases being due to non-git causes. It is a benign condition with good long-term outcome. One should keep his mind open as infantile colic may be a manifestation of other hidden pathologies. Management of infantile colic remains an open issue with Cimetropium bromide as a new promising drug.
2.IBS and the role of otilonium bromide
Guy Boeckxstaens & Enrico S. Corazziari & Fermín Mearin & Jan Tack. Int J Colorectal Dis (2013) 28:295–304
Antispasmodic agents are a heterogeneous class of agents that decrease the tone and contractility of intestinal smooth muscle. Mechanisms of action vary but divide broadly into those directly affecting intestinal smooth muscle contractility by acting on calcium channels (musculotropic spasmolytics such as otilonium bromide (OB), peppermint oil, pinaverium bromide, and mebeverine) and those with anticholinergic/anti-muscarinic properties such as dicyclomine, hyoscyamine, cimetropium bromide, and prifinium bromide. Unlike musculotropic spasmolytics, which are usually devoid of action outside of the gastrointestinal tract [65, 66], anticholinergic agents not only act on gastrointestinal smooth muscle (causing constipation), but also bind to muscarinic receptors in other body tissues leading to other anticholinergic effects such as dry mouth, tachycardia, and impaired vision.
3.Irritable Bowel Syndrome
Joel A. Sach, Lin Chang. Current Treatment Options in Gastroenterology 2002, 5:267–278
Dosages have varied across studies. The six agents evaluated in the above-mentioned meta-analysis consisted of cimetropium bromide 150 mg, hyoscine butyl bromide 30 to 40 mg, mebeverine 400 mg, otilonium bromide 120 to 320 mg, pinaverium bromide 150 mg and trimebutine 300 to 600 mg used for a duration of 2 to 24 weeks. Unfortunately, none of these agents are available in the United States. Dicyclomine bromide (Bentyl, Aventis Pharmaceuticals, Bridgewater, NJ), although not considered by the authors of the above-mentioned meta-analysis to have been studied in a high-quality manner, has been reported to be effective in reducing fecal urgency and pain. Also, Bentyl is available in the United States. Although the dosage used in this study was 40 mg QID, in clinical practice, these agents are shown to retain efficacy when used on an as-needed basis up to two times a day and become less effective with long-term use. The typical recommended dosage for dicyclomine bromide (Bentyl) is 10 to 20 mg PO BID PRN for pain and discomfort, with maximal allowed daily dose of 40 mg PO QID.
2005 - BOC Sciences | All rights reserved
DOWNLOAD